Vireo Growth Inc. (VREOF): Total Assets
$817.15M
As of 2025-12-31
$1.27B
As of 2026-06-30
+72.5%
3-year compound annual growth
+51.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $817.15M | +193.0% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $278.86M | +52.2% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $183.26M | +15.1% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $159.16M | -4.7% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $166.97M | +62.7% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $102.63M | n/a | 2022-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $817.15M | +193.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.56B | +65.7% |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $717.90M | -34.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
Compare VREOF, LGND, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗